 Mylan Inc. raised its bid for Swedish drug maker Meda AB to $6.7 billion, according to a person familiar with the matter.. The offer, all stock, represents a 50% premium to the share price of just below 100 Swedish kronor (about $15) when the Financial Times broke news of a Mylan overture earlier this month. At 145 kronor, the deal would value Meda at about $6.7 billion.. Early...
  